Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
Annals of the Rheumatic Diseases, 2020 Background Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate response or intolerance to at least one biologic disease-modifying ...
P. Mease +13 more
semanticscholar +1 more source
Psoriatic arthritis and the association with cardiometabolic disease: a narrative review
Therapeutic Advances in Musculoskeletal Disease, 2021 Psoriatic arthritis (PsA) is associated with a higher burden of cardiometabolic disorders, such as hypertension, dyslipidemia, diabetes, obesity, and cardiovascular disease (CVD), compared with the general population.
P. Karmacharya, A. Ogdie, L. Eder
semanticscholar +1 more source
Secukinumab in the treatment of psoriasis: patient selection and perspectives. [PDF]
, 2018 Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Beck, Kristen M +2 more
core +1 more source
Alterations of the Skin and Gut Microbiome in Psoriasis and Psoriatic Arthritis
International Journal of Molecular Sciences, 2021 Numerous scientific studies in recent years have shown significant skin and gut dysbiosis among patients with psoriasis. A significant decrease in microbiome alpha-diversity (abundance of different bacterial taxa measured in one sample) as well as beta ...
I. Olejniczak-Staruch +5 more
semanticscholar +1 more source
Secukinumab versus adalimumab for psoriatic arthritis: comparative effectiveness up to 48 weeks using a matching-adjusted indirect comparison [PDF]
, 2018 Secukinumab and adalimumab are approved for adults with active psoriatic arthritis (PsA). In the absence of direct randomized controlled trial (RCT) data, matching-adjusted indirect comparison can estimate the comparative effectiveness in anti-tumor ...
Gandhi, Kunal +8 more
core +2 more sources
The Epidemiology of Psoriatic Arthritis Over Five Decades: A Population‐Based Study
Arthritis & Rheumatology, 2021 To determine the incidence of psoriatic arthritis (PsA) in a US population and describe trends in incidence and mortality over 5 decades.
P. Karmacharya +10 more
semanticscholar +1 more source
International Journal of Molecular Sciences, 2020 Psoriasis is a chronic inflammatory skin disease characterized by scaly indurated erythema. It impairs patients’ quality of life enormously. It has been recognized not only as a skin disease but as a systemic disease, since it also causes arthritis ...
M. Kamata, Y. Tada
semanticscholar +1 more source
MRI changes in psoriatic dactylitisextent of pathology, relationship to tenderness and correlation with clinical indices [PDF]
, 2008 Objectives. To quantify the extent of inflammation in psoriatic dactylitis and to examine the relationship between clinical and magnetic resonance imaging (MRI) data in both tender and non-tender dactylitis. Methods.
Chandramohan, M. +3 more
core +1 more source
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis. [PDF]
, 2018 To compare disease burden and biologic use among psoriatic arthritis (PsA) or rheumatoid arthritis (RA) patients recruited to the Corrona registry. Retrospective study of patients with PsA or RA enrolled in Corrona between January 2002 and March 2013 and
Etzel, Carol J +6 more
core +1 more source
Annals of the Rheumatic Diseases, 2020 Objectives MAXIMISE (Managing AXIal Manifestations in psorIatic arthritis with SEcukinumab) trial was designed to evaluate the efficacy of secukinumab in the management of axial manifestations of psoriatic arthritis (PsA).
X. Baraliakos +10 more
semanticscholar +1 more source